CAR-T Cell Therapy for Large B-Cell Lymphoma: How It Works and How It Differs from Stem Cell Transplant

Research-informed explainer — last updated April 12, 2026

CAR-T cell therapy — in which a patient's own T cells are genetically reprogrammed to hunt and destroy lymphoma cells — now achieves event-free survival superior to salvage chemotherapy followed by autologous stem cell transplant in patients with relapsed or refractory large B-cell lymphoma who fail first-line treatment. The procedure is complex, requires a specialized center, and carries unique risks including a potentially life-threatening inflammatory response, but for eligible patients it offers a meaningful chance at durable remission where other options have failed.

The research behind this treatment comes from specialists at major cellular therapy centers. Sattva Neelapu, Professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center, published the SCHOLAR-1 study benchmarking outcomes in chemotherapy-refractory DLBCL before CAR-T was available (1,639 citations) and the authoritative review of cytokine release syndrome and associated neurotoxicity (961 citations). Lori Leslie, Director of Indolent Lymphoma and CLL Research Programs at John Theurer Cancer Center in Hackensack, contributed to ZUMA-7 — the randomized phase III trial directly comparing CAR-T to chemo/transplant in second-line large B-cell lymphoma (1,432 citations) — and the 4-year survival update (374 citations). Tatyana Feldman, Director of the T-Cell Lymphoma Program at John Theurer Cancer Center, co-authored the first published report of successful CAR-T treatment of chemotherapy-refractory DLBCL (1,601 citations) and published on epcoritamab, a bispecific antibody that represents an alternative for patients who cannot receive CAR-T or who relapse after it (494 citations). David Maloney, Medical Director of Cellular Immunotherapy at Fred Hutchinson Cancer Center in Seattle, contributed foundational work on CAR-T cell composition — specifically the importance of the CD4:CD8 ratio — that informs how CAR-T products are manufactured today (2,064 citations).

What is large B-cell lymphoma and when does relapse occur?

Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma in adults. It is treated first with R-CHOP chemotherapy (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone), which cures approximately 60% of patients. The remaining 40% either do not respond to first-line treatment or relapse within two years — and for these patients, the historical standard was salvage chemotherapy followed by autologous stem cell transplant (ASCT). SCHOLAR-1 data from Neelapu's group showed that patients with truly refractory disease had an objective response rate of only 26% to salvage regimens and a median overall survival of 6.3 months.

How CAR-T cells are made: the manufacturing process

CAR-T therapy begins with leukapheresis — a procedure in which blood is drawn and T cells are separated out. These cells are sent to a manufacturing facility, where a gene encoding a chimeric antigen receptor (CAR) targeting CD19 (a protein expressed on B cells and most B-cell lymphomas) is inserted into the T cells. The engineered cells are then expanded — grown in large numbers — and shipped back to the treatment center.

David Maloney's work at Fred Hutchinson demonstrated that the composition of the CAR-T product matters. Products manufactured with a defined 1:1 ratio of CD4 and CD8 T cells achieved higher complete remission rates and better expansion in vivo. This research shaped how second-generation CAR-T products are designed.

Manufacturing typically takes 2–4 weeks. During this period, most patients receive bridging chemotherapy to control disease growth while waiting. This is also when your care team evaluates whether you are fit enough for the infusion itself.

The ZUMA-7 trial: CAR-T versus stem cell transplant head-to-head

Until 2022, CAR-T was approved only for patients who had failed two or more prior lines of therapy. ZUMA-7, to which Lori Leslie contributed, changed that. The trial enrolled 359 patients with early relapsed or refractory DLBCL and randomly assigned them to axicabtagene ciloleucel (axi-cel, Yescarta) or standard-of-care salvage chemo followed by high-dose chemotherapy and autologous stem cell transplant.

Event-free survival — the primary endpoint — was 8.3 months with axi-cel versus 2 months with chemo/transplant. The 4-year overall survival update showed 54.6% versus 46% in favor of CAR-T. Critically, axi-cel produced these results in a single infusion, compared with the months-long process of salvage chemo, transplant eligibility assessment, mobilization, conditioning, and post-transplant recovery.

What the procedure feels like: the patient timeline

1. Leukapheresis (day 0): Blood draw lasting 3–4 hours; T cells are separated and sent for manufacturing.
2. Bridging therapy (weeks 1–4): Chemotherapy to control disease while cells are made.
3. Lymphodepleting chemotherapy (days -5 to -3): Fludarabine and cyclophosphamide are given to reduce competing immune cells and prepare the body to receive CAR-T cells.
4. CAR-T infusion (day 0): A single IV infusion, typically lasting 30 minutes.
5. Monitoring period (days 1–14): Most programs require patients to remain near the treatment center. Close monitoring for cytokine release syndrome and neurotoxicity.
6. Disease assessment (weeks 4–8): PET scan to evaluate response.

Cytokine release syndrome and neurotoxicity: the specific risks

Sattva Neelapu's review of cytokine release syndrome (CRS) describes the mechanism clearly: when infused CAR-T cells encounter tumor cells and activate, they release large amounts of inflammatory cytokines including IL-6. This causes CRS, which ranges from fever and flu-like symptoms (grade 1–2) to dangerous hypotension, hypoxia, and organ dysfunction (grade 3–4). The anti-IL-6 antibody tocilizumab is the primary treatment for severe CRS and has substantially reduced deaths from this complication.

Immune effector cell-associated neurotoxicity syndrome (ICANS) — confusion, tremors, difficulty writing, seizures — occurs independently of CRS and requires corticosteroid treatment. Most neurotoxicity is reversible, but a small percentage of patients experience severe or prolonged deficits.

Grade 3–4 CRS occurs in approximately 23% of patients receiving axi-cel; grade 3–4 ICANS in approximately 25%. Treatment-related deaths occur in less than 3% of cases at experienced centers.

When CAR-T is not feasible: bispecific antibodies as an alternative

For patients who cannot access or tolerate CAR-T — due to age, organ function, or inability to wait for manufacturing — bispecific T-cell engaging antibodies offer an off-the-shelf alternative. Tatyana Feldman's work on epcoritamab (a subcutaneous CD3xCD20 bispecific) showed a 63% overall response rate and 39% complete response rate in heavily pretreated large B-cell lymphoma, including patients who had already received CAR-T. Epcoritamab is now FDA-approved and provides an option when cellular therapy is not accessible.

Questions to ask your doctor

• Am I eligible for CAR-T therapy now, or do I need to fail an additional line of chemotherapy first?
• Does my treating center have experience managing cytokine release syndrome, and how many CAR-T infusions have been given here?
• How long will the manufacturing process take, and what bridging therapy will I receive in the meantime?
• What are the signs of cytokine release syndrome and neurotoxicity, and what should prompt an emergency visit?
• If CAR-T is not an option for me, is a bispecific antibody such as epcoritamab or mosunetuzumab available?

The bottom line

CAR-T cell therapy using axicabtagene ciloleucel has become the preferred second-line option for relapsed or refractory large B-cell lymphoma, with the ZUMA-7 trial demonstrating event-free survival more than four times longer than salvage chemotherapy plus transplant. The procedure requires a specialized center, a manufacturing wait of several weeks, and careful monitoring for a distinctive set of immune-related toxicities. For patients who relapse early or whose disease does not respond to first-line R-CHOP, asking your oncologist whether you are a CAR-T candidate should be an immediate priority.